We help to build your life sciences business





The Venture Challenge generates impact for society by turning research results into a solid business case

In the Venture Challenge you learn to analyze customer value propositions, to identify key risks and assumptions, to develop a validation and de-risking strategy, to build a venture plan and you are connected to experts, experienced entrepreneurs and funders.



Winner 2022

Read our special e-magazine for more results and success stories of 15 years LS@W & Venture Challenge

LifeSciences@Work **Succes Stories** 15 YEARS

Special Edition – 15-year anniversary



www.lifesciencesatwork.nl



venture challenge and LS@W has sparked a new generation of Life Sciences entrepreneurs







LS@W Mentornetwerk

'It took four months before I said yes. I initially didn't want to do it because my experience lies in MedTech. I eventually accepted the role of CEO with the condition that I would have Dinko Valerio, a highly experienced pharma entrepreneur, as my business coach.'

- Eline van Beest, CEO Hybridize Therapeutics and alumnus of 2010



'Without my mentor by my side, we could never have gotten CE approval in two years and FDA clearance within three years.'

- Bram Schermers, CEO Sirius Medical and alumnus of 2015





'What it means to bring a drug to market is something no course can teach. That is why having an experienced entrepreneur on board is an absolute must.'

- Marc van Moorsel, COO of TargED and alumnus of 2018



INTRODUCING

The LifeSciences@Work Advisory Board



Hans Schikan

Experienced Entrepeneur Chairman, Board member, Former Special Envoy for Vaccines Linkedin



Carmen van Vilsteren

Investor Chair Topsector Life Sciences & Health Linkedin



Nettie Buitelaar

Experienced Entrepreneur CEO at Biotech Booster Linkedin



Allard Kaptein Experienced Entrepreneur CEO at Genase Therapeutics CStrato at IMMIOS Therapeutics | Chair of Board at Immagene Linkedin



Varsha Thakoersing

Alumnus CEO at IMcoMET | CEO at Caladrius Technologies Linkedin



Alumnus

Founder and Chief Innovation

Officer at Hybridize Therapeutics

Linkedin

Lonneke Baas

ROM Senior Business Developer InnovationQuarter Linkedin



Kim Lucassen

Legal Partner at Loyens & Loeff - Life sciences Linkedin



Geert-Jan Mulder

Investor Managing Partner Forbion Linkedin



Brigitte Drees Science Park CEO at Pivot Park and Pivot Park Screening Centre Linkedin



Joram Sjoerts University aging Director Valorisation

University Managing Director Valorisation at Radboud university medical center Linkedin



Some of the people that have already contributed as speaker, expert, mentor, or jury

lifesciences @work





Partners LifeSciences@Work



Ministerie van Economische Zaken en Klimaat

Health~Holland

LOYENS LOEFF pivetpark



GameChanger CHALLENGE







venture challenge Apply for the Venture Challenge



8 jan 2024, proefdiervrij.nl

7 Feb 2023, nwo.nl/vc





And now for the Venture Challenge Fall 2023 winner





VC2023 Fall: Meet the teams







XS innovations





DEMAND FOR RADIOLOGY SERVICES IS ON THE RISE.

Hospitals struggle with increasing workload and a shortage of radiologists. WE PROVIDE OncoRead: AN AI PLATFORM FOR RAPID AND ACCURATE DIAGNOSIS OF ONCOLOGY CT STUDIES.







Market size of

€ 280 M

by 2026.

Heparanase inhibition technology prevents metastasis in vivo



Gijs Ruijgrok: g.ruijgrok@lic.leidenuniv.nl Vincent Lit: v.a.j.lit@lic.leidenuniv.nl

Heparanase inhibition technology

Improve anti-cancer treatments

Prevent metastasis in 90% of the cancers

Lumox

Sebas Pronk Irati Beltrán Hernández Sabrina Oliveira Danielle Counotte

Killing cancer with minimal side effects due to two levels of safety



Tumor Specific Notch Inhibition to cure Triple Negative Breast Cancer

GSI

Target Specific Treatment

TODAYS TREATMENT

Target AND Tumor Specific Treatment

TOMORROW'S TREATMENT

Fenix

Therapeutics

Effective but dose limiting Side Effects No Cure Lives LOST Negative impact on Society

FENIX-GSI FTX-GSI 'drug active in tumor only' **Compelling preclinical In vivo data** in TNBC tumors Effective No dose/duration limit No side effects Cure Lives GAINED Positive impact Society

Future: Broad application to other Notch driven tumors



depredict

Al antidepressant decision support tool



- O First evidence-based decision support tool in mental health
- O Seeking 4M investment to enter the market
- O 13M revenue in year 7
- O Expansion to other mental health disorders
- O Let's change mental health care!

XS Innovations resolves the root cause of hemodialysis access complications: Continuous high blood flow

A surgically created artery-vein connection is required for a high-flow vascular access site...



XS innovations

vascular

access solutions



Poor access patency

Heart failure

Steal syndrome

Aneurysms

Long compression times and risk of bleeding ...which can be resolved by opening the access only during hemodialysis

The DAVF: "Dynamic AVF"

OPEN: Increased blood flow for hemodialysis

CLOSED:

Normal blood circulation



www.xs-innovations.com

And the winner is...





Opportunities don't just happen, we create them!

Join our community



www.lifesciencesatwork.nl



